← Eichor
Study identifier: NCT04691817 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Condition: Lung Cancer, Nonsmall Cell  ·  Sponsor: Abramson Cancer Center at Penn Medicine

PhasePhase 1/Phase 2
Planned participants28
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Melissa Volpe, BA  ·  215-220-9703  ·  melissa.volpe@pennmedicine.upenn.edu

Melina Marmarelis, MD, MSCE  ·  215-615-5835  ·  melina.marmarelis@pennmedicine.upenn.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04691817